SEC Filings | Aerie Pharmaceuticals, Inc
Aerie in Europe - EuroTimes
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Aerie Pharma: Finding Value In The Ophthalmic Space (NASDAQ:AERI) | Seeking Alpha
Aerie Pharma: Significantly Derisked (NASDAQ:AERI) | Seeking Alpha
Aerie Pharma: 80% Upside While The Moon Shot Awaits (NASDAQ:AERI) | Seeking Alpha
Should Aerie Pharmaceuticals Inc (AERI) be in Your Portfolio? - InvestorsObserver
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Aerie Pharma (AERI) Provides 2020 Company and Guidance Update Associated with COVID-19
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals Inc - AnnualReports.com
AERIE PHARMACEUTICALS, INC. : AERI Stock Price | MarketScreener
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
Aerie Pharmaceuticals Launches GMP Facility - Contract Pharma
Aerie Pharma's CMO Receives FDA CRL - Contract Pharma
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharma appoints Richard Rubino as CFO | Procurement & Supply Chain | Healthcare Global
FDA OK of Aerie Pharma glaucoma drug jeopardized by factory issues out of its control
Eye disease drug firm Aerie Pharma acquires Spanish company for $10M | WRAL TechWire
Aerie Pharmaceuticals – Capital Sign Solutions
